4/8/2013

Vertex Pharmaceuticals and Bristol-Myers Squibb signed a non-exclusive deal to initiate two midstage trials of a once-a-day combination therapy for hepatitis C. The trials will test the safety, tolerability, pharmacokinetics and viral cure rates of Vertex's VX-135, a nucleotide analogue hepatitis C virus polymerase inhibitor, in combination with Bristol's daclatasvir, an experimental NS5A replication complex inhibitor.

Related Summaries